Notice of Change in Eligible Organizations in PA-18-629 “Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)" to Allow Foreign Components in Domestic Applications

Notice Number: NOT-CA-18-059

Key Dates
Release Date: March 26, 2018

Related Announcements
PA-18-629

Issued by
National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to amend PA-18-629 "Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)" so that Foreign components can be part of applications from Domestic institutions that are submitted in response to it.

 

The following specific change is implemented:

Part 2. Section III. Eligibility Information
1. Eligible Applicants

Eligible Organizations

The language towards the end of the bulleted organizations/institutions in this section of PA-18-629 currently reads as follows:

Foreign Institutions
Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

That language has been revised and implemented as follows:

Foreign Institutions
Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

All other aspects of this Funding Opportunity Announcement remain unchanged.

Inquiries

Please direct all inquiries to:

Anne Menkens, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-6510
Email: menkensa@mail.nih.gov